Clinical trial
Infliximab in Treating Patients With Myelodysplastic Syndrome
NCT00074074 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00074074 |
|---|---|
| Title | Infliximab in Treating Patients With Myelodysplastic Syndrome |
| Official title | Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Biological |
| Interventions | infliximab |
| Enrollment | 46 |
| Start date | Oct 1, 2003 |
| Primary completion | Dec 1, 2006 |
| First posted | Dec 11, 2003 |
| Last update posted | Jul 16, 2012 |
| Countries | Belgium, Czechia, France, Germany, Italy, Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: